Multimodality Therapy Nic Denko Radiation Biology 2011.

Slides:



Advertisements
Similar presentations
Edited version of presentation given at RSNA
Advertisements

Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.
Progress Against Head and Neck Cancer. 1970–1979.
Understand broad treatment strategies in the treatment of tumors.
Advances and Emerging Therapy for Lung Cancer
Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD.
CANCER CHEMOTHERAPY. Anti Cancer drugs: 1.Historically derived small molecules. Target DNA structure or segregation of DNA- Conventional chemotherapy.
Randomized Trial of p53 Targeted Adjuvant Therapy for Patients (pts) With Organ-Confined Node-Negative Urothelial Bladder Cancer.
‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.
Modifiers of Cell Survival: Oxygen Effect
Radiation Therapy (RT). What is cancer? Failure of the mechanisms that control growth and proliferation of the cells Uncontrolled (often rapid) growth.
1 Antimicrobial Therapy Chemotherapy: any treatment of patient with chemicals to treat a condition. –Now word associated with cancer treatment –Our focus.
Andrea Janeš Mentor: A. Žmegač Horvat
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
  Surgery  Hormone Therapy  Radiation  Chemotherapy  Immunotherapy  Targeted therapy Methods of Treatment
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Upper gastrointestinal cancers
Cancer vaccines are biological response modifiers. They prime the immune system to attack the cancer cells in the body. The goal is to prevent or to treat.
Introducing Apceden™.
CANCER. THE WORD CANCER  FEAR  DEATH  PAIN  SUFFERING  LOSS  ECONOMIC LOSS  DISFIGUREMENT  WHAT’S THE FUTURE.
Understanding Cancer Accelerated Biology. Faces of Cancer  You are a doctor interviewing a person (the piece of paper you got on the way in) with cancer.
Margaret Tempero, M.D. Professor of Medicine University of California, San Francisco Debate: This house believes that FOLFIRINOX is the best treatment.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 100 Basic Principles of Cancer Chemotherapy.
New Developments in Cancer Treatment Dulcinea Quintana, MD.
 Identify different options of cancer therapy.  Most cancers are treated with a combination of approaches.
First Year Workshop 2014 Miriam Lafiandra
Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”
Adaptive Response to Low Dose Radiation
Evidence Based For invasive breast cancer BCT is Tumor excision, axillary node dissection, whole breast radiation Modified mastectomy is total mastectomy.
Chapter 23 Spring 2005 Presented by: Tiffany Marie Thoren Molecular Cell Physiology Dr. James Enderby Bidlack Cancer.
IGF-1R: A key linker between chemoresistance and cancer stem cells in epithelial ovarian cancer cells Ram Kumar Singh, Ankit Jinager, Ajit Dhadwe, Abhijit.
Heat Shock Protein 90 (HSP90) is over-expressed in p16 negative oropharyngeal squamous cell carcinoma and its inhibition in vitro potentiates the effects.
Cancer cells grow and divide out of control Section 9.4.
Other Modes of Treatment
Adjuvant chemotherapy – When should surgeons recommend? Joint Hospital Surgical Grand Round Dr Lorraine Chow Ruttonjee Hospital.
Cancer Basics EQ: What does cancer have to do with the cell cycle?
Homework #3 is due 11/15 Bonus #2 is posted No class on 11/20.
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
Tumor Heterogeneity and Chemotherapy Resistance: The Fault in Our Cells Koch Institute for Integrative Cancer Research MIT.
Regents Biology Mitosis & Cancer: When Making New Cells Goes Terribly Wrong!
Cancer Therapies DNA microarrays are used to assess the relative expression of thousands of genes simultaneously—relative expression means that.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
RISE Honors Seminar 2014 Ronald Doll RISE Dept. S-332 X 3168 Training – Synthetic Organic Chemist (Ph.D. Duke Univ.) - National Institute.
UNIVERSAL SURVIVAL CURVE AND SINGLE FRACTION EQUIVALENT DOSE: USEFUL TOOLS IN UNDERSTANDING POTENCY OF ABLATIVE RADIOTHERAPY CLINT PARK, M.D. M.S., LECH.
Cancer Chemotherapy Part I: General Cancer Chemotherapy Chapter 16; Pages 797 to 815A also Section 16.11: Drug Resistance Folder Title: CxChemoPart1(NoTP)
Cancer cells grow and divide out of control Ch. 9.4.
ABIRA KHAN TUMOR MARKERS & CANCER TREATMENT. TUMOR MARKERS Biological substances synthesized and released by cancer cells or produced by the host in response.
Chapter 12 Therapeutic Heating Applications of Radio Frequency Energy C-K. Chou.
WP2. Combined effect of charged particles irradiation and anticancer drugs in cultured human tumor cells (Milano and Roma 3, collaboration with CNAO and.
PRINCIPLES OF ANTIBIOTIC THERAPY
종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.
Statistics (from the National Institutes of Health) on average, in the US, people have a 2 in 5 lifetime risk of developing cancer second leading cause.
Folder Title: CxChemoPart1
Cancer Chemotherapy.
Metastatic Head Neck Cancer and Immunotherapy
Dr. Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
Basic Principles of Cancer Chemotherapy
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Chemotherapy Day 2.
Regulating the Cell Cycle
Current RTOG Soft Tissue Sarcoma Trials
Figure 3 Drug cycling with collateral sensitivity
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
Cancer is a Challenge Cancer is common in humans – a public health problem ~1 of every 3 women will develop cancer ~1 of every 2 men will develop cancer.
Genetic and pharmacologic inactivation of KSR1 radiosensitizes A431 cells in vitro to the lethal effect of ionizing radiation. Genetic and pharmacologic.
Volume 21, Issue 8, Pages (August 2013)
Principles of Antimicrobial Therapy
Presentation transcript:

Multimodality Therapy Nic Denko Radiation Biology 2011

Cancer is a systemic disease Therapeutic modalities can be either localized, (such as radiation or surgery), or systemic (such as chemotherpy) To treat cancer we need to think about combining the best of the various modalities to eradicate tumor cells (or make them dormant)

How much cell killing is needed? 10^9 cells per ml 100 mls of tumor 10^11 clonogens Surgical debulking removes 99% of tumor, still left with 10^9 clonogens that need to be killed. Radiation and chemo needed for eradication.

Radiation can be combined with Surgery (possible IORT or adjuvant) Conventional chemotherapy (before, during or after XRT) Molecularly targeted chemotherapy Non-standard modalities such as heat, RIT, PDT

We would like to “synergize” therapies Additive killing is ok, as long as toxicities are not overlapping as well (ie myelosupression versus renal toxicity) We would like to rationally add modalities to achieve more than additive toxicities Consider mechanism of killing, timing of doses, and mechanism of repair

Isobologram Drugs A and B have equal potency at concentrations A and B (ie IC50). Combinations that give the same effect but fall below the line are superadditive Combinations that give the same effect but fall above the line are antagonistic

XRT with Temzar For GBM

Two very different mechanisms Of cell kill by conventional chemotherapies

Synthetic Lethality

Mechanism of Cell Kill for Different Agents

Response of Stomach cancer cells To various chemotherapies

Cellular Response to Taxanes in vitro

How to combine XRT with Chemo? Boost to bulky diseaseSites where chemo cannot penetrate

Taxanes can radiosensitize through modification of the cell cycle

9% increase in survival With the addition of Cetuximab to XRT for HNC Presence of Rash Predicts for response

Drugs can have +/- OERs

Oxygen as a Drug Modifying Factor

Tumor Cell Heterogeneity Leads to selection of resistant Clones over time

MDR (resistant) cells are not resistant to Radiation

Heat is toxic to cells

Peripheral tumors can be more easily heated

Effects of HT on immune function

Randomized phase 3 trial Showing a benefit of Adding heat to XRT for Superficial tumors Chest wall recurrences

Novel use of Heat to Target Tumors

Summary Radiation is one tool in the oncologists toolbox How can we rationally combine it with other tools to get 10^11 logs of cell kill Can we combine modalities with genetics to achieve synthetic lethality